Desmoid Tumors Pipeline

DelveInsight’s, “Desmoid Tumors - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Desmoid Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Desmoid Tumors: Understanding

Desmoid Tumors: Overview

Desmoid tumors, also known as desmoid-type fibromatosis, are rare, non-metastatic soft tissue tumors that arise from the connective tissues, specifically the fibroblasts, in the body. These tumors are characterized by their aggressive local growth and potential to invade surrounding tissues, though they do not spread to distant organs. They most commonly develop in the abdominal wall, limbs, and trunk, but can occur anywhere in the body. Desmoid tumors are associated with mutations in the APC gene or the CTNNB1 gene, which lead to abnormal regulation of cell growth and proliferation.

The clinical presentation of desmoid tumors varies significantly depending on their location and size. Symptoms often include a noticeable mass or swelling, pain, and sometimes functional impairment of the affected area. Due to their infiltrative nature, these tumors can be challenging to treat, often requiring a combination of surgery, radiation therapy, and pharmacological approaches such as nonsteroidal anti-inflammatory drugs (NSAIDs), hormone therapy, or chemotherapy. Despite treatment, recurrence rates are high, necessitating close and long-term follow-up for affected individuals.

The management of desmoid tumors is complex and tailored to the individual, taking into account factors such as tumor size, location, growth rate, and the patient's overall health. In some cases, a watchful waiting approach is adopted, particularly for asymptomatic tumors, given the potential for spontaneous regression and the significant morbidity associated with aggressive treatments. Advances in understanding the molecular biology of desmoid tumors are driving the development of targeted therapies, offering hope for more effective and less invasive treatment options in the future.

"Desmoid Tumors- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Desmoid Tumors pipeline landscape is provided which includes the disease overview and Desmoid Tumors treatment guidelines. The assessment part of the report embraces, in depth Desmoid Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Desmoid Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Desmoid Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Desmoid Tumors.

Desmoid Tumors Emerging Drugs Chapters

This segment of the Desmoid Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Desmoid Tumors Emerging Drugs

• AL102: Immunome

AL102 is an investigational small molecule gamma secretase inhibitor currently being evaluated for the treatment of desmoid tumors – a debilitating soft tissue malignancy. AL102 is a potential once-daily oral treatment for desmoid tumors. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Desmoid Tumors. 

Further product details are provided in the report……..

Desmoid Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Desmoid Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Desmoid Tumors

There are approx. 4+ key companies which are developing the therapies for Desmoid Tumors. The companies which have their Desmoid Tumors drug candidates in the most advanced stage, i.e. Phase III include, Immunome.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Desmoid Tumors: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Desmoid Tumors therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Desmoid Tumors drugs.

Desmoid Tumors Report Insights

• Desmoid Tumors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Desmoid Tumors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Desmoid Tumors drugs?
• How many Desmoid Tumors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Desmoid Tumors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Desmoid Tumors therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Desmoid Tumors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Immunome
• Iterion Therapeutics

Key Products

• AL102 
• Tegavivint